This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit Newshome.
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin- For Non-US/Non-UK/Non-Canadian Media
New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans- For Non-US/Non-UK/Non-Canadian Media
FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin
Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention
The Education Hub on Newshome offers the latest information regarding